Skip to main content
. 2020 Jan 27;64(2):e01729-19. doi: 10.1128/AAC.01729-19

FIG 4.

FIG 4

Simulations for protection in female genital tract (FGT) tissue (a) and rectal tissue (b) based on patient adherence (given by number of doses per week). Maraviroc was predicted to show increased efficacy combined with emtricitabine in the FGT (>90% protection at two doses/week) and combined with tenofovir in the rectal tissue (>90% protection with one dose/week).